Does CLDX pay a dividend and is it safe?

Celldex Therapeutics Inc. (CLDX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / CLDX / dividends

NEOG (47) NTLA (25) QDEL (21) ORKA (53) ⌘ Pro Terminal →

Celldex Therapeutics Inc. (CLDX) Dividend Safety Gauge & 10-Year DRIP Compounder

$30.10 +0.70% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $30.08

Celldex Therapeutics Inc. (CLDX) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.36B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLDX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CLDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Celldex Therapeutics Inc. (NASDAQ: CLDX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $30.10 (+0.70% 1D, market cap $2.36B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CLDX ranks #820 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CLDX compare to NEOG and NTLA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), CLDX carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 87.1%, and ROIC of -35.0%. By comparison, NEOG (Neogen Corporation) holds a D grade (47/100 RQD, P/E N/A, ROIC -0.6%, cap $2.58B) and NTLA (Intellia Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $1.75B). Among the 5-stock peer group, CLDX leads on earnings multiple (N/A) while NEOG leads on capital efficiency (-0.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLDX?

▼

Per CLDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000744218), Celldex Therapeutics Inc. generated $1.5M in revenue (-78.0% YoY), -$258.8M in net income, and -$213.7M in free cash flow against $583.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $30.08 (-0.06%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLDX)Realized 20D OHLCV Swing Band: ±8.7%

Deterministic 5-Pillar Attribution (29/100 Composite)

🔍 WHY CLDX SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (31% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 87.1% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)

Altman Z-Score 20.25 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$28.25+7.2% Next Q

Q2 (-2Q)

Grade E$30.29-0.5% Next Q

Q3 (-1Q)

Grade E$30.15-0.2% Next Q

Current

Grade E$30.10-9.8% Hist 90D α

Trajectory: E (21) → E (29)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLDX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLDX currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($33.64) and Max Pain ($31.61) forces dealer call-delta covering toward $47.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CLDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 29%NO 71%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLDX)

✓Walkthrough of CLDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CLDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.15%📐 HORIZONTAL RANGE

2026-11-03O $29.89H $30.10L $29.89C $30.10VOL 870.8K

RES: $42.39SUP: $26.31SMA50: $33.64SMA200: $32.69

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLDX Butterfly Map → + Track CLDX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -78.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CLDX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLDX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CLDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLDX)

Health Care Rank #820 of 1015 ⚔️ NEOG vs CLDX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLDX vs. NEOG, NTLA, QDEL, ORKA)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Celldex Therapeutics Inc. (CLDX) ranks #820 by composite RQD confidence (29/100, grade E) and #225 by equity capitalization ($2.36B). Within this direct 5-issuer industry benchmark cohort, CLDX leads on earnings valuation at N/A trailing P/E, while NEOG leads on capital efficiency and profitability with -0.6% ROIC and 46.9% gross margin. ORKA currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with CLDX at 29/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CLDX ACTIVE Celldex Therapeutics Inc.	E	29/100	—	87.1%	-35.0%	+0.70%	$2.36B	Benchmark Subject
NEOG Neogen Corporation	D	47/100	—	46.9%	-0.6%	-3.59%	$2.58B	/neog-vs-cldx →
NTLA Intellia Therapeutics Inc.	E	25/100	—	—	-35.0%	-5.74%	$1.75B	/ntla-vs-cldx →
QDEL QuidelOrtho Corporation	E	21/100	—	—	-35.0%	-3.71%	$908.6M	/qdel-vs-cldx →
ORKA Oruka Therapeutics Inc.	D+	53/100	—	—	-18.8%	+0.23%	$6.41B	/orka-vs-cldx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000744218 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Celldex Therapeutics Inc. (CLDX) reported GAAP revenue of $1.5M (-78.0% vs. FY2024 revenue of $7.0M , and -77.6% cumulative change since FY2023) , GAAP net income of -$258.8M, operating cash flow of -$210.9M, and free cash flow of -$213.7M (-33.8% YoY). On the balance sheet, CLDX closed FY2025 with $583.0M in total assets against $0 in total debt (Altman Z-Score: 20.25, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.5M	-$258.8M	-$210.9M	-$213.7M	$583.0M	—
FY2024 (FY)	2024-12-31	$7.0M	-$157.9M	-$157.8M	-$159.7M	$792.3M	—
FY2023 (FY)	2023-12-31	$6.9M	-$141.4M	-$107.3M	-$107.3M	—	—

3. CLDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CLDX compare to NEOG and NTLA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CLDX?

Where is CLDX trading relative to its 50-day, 200-day, and 52-week technical levels?

CLDX last traded at $30.10 (+0.70% on volume of 870,792 shares), positioning the stock -10.52% below its 50-day simple moving average ($33.64) and -7.92% below its 200-day simple moving average ($32.69). Across its 52-week range of $22.10 to $45.14, CLDX sits at the 34.7% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±8.7% ($27.48 to $32.72).

Direct Sub-Reports: CLDX RQD Cockpit CLDX 12M Forecast CLDX Earnings & Move CLDX Dividends & DRIP CLDX Insiders & 13F CLDX Whale Options CLDX Profit Sankey CLDX News & Why

ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

CLDX — Celldex Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Celldex Therapeutics Inc. (CLDX) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $30.10 (+0.70% 1D, market capitalization $2.36B).

Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 87.1%, operating margin of -60.0%, and free cash flow yield of -9.10%.
Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (3/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 20.25, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Celldex Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry,. Reported revenue was $1.5M in FY 2025, $7.0M in FY 2024, and $6.9M in FY 2023, . — for further detail on how the company monetizes its offerings.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Celldex Therapeutics Inc. (CLDX) reported $1.5M in annual revenue (up from $7.0M in FY2024, -78.0% YoY) and -$258.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($6.9M revenue, -$141.4M net income) through FY2025, CLDX scaled operating cash flow to -$210.9M and free cash flow to -$213.7M, backed by $583.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -9.10% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $22.10 – $45.14 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), CLDX carries a macro regime beta of 1.00 and gross margin of 87.1%.

Key Question #1: Can CLDX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.5M and free cash flow of -$213.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is CLDX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CLDX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Celldex Therapeutics Inc. (CLDX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CLDX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

Celldex Therapeutics (CLDX) Stock Looks Rich After Shareholder Investigation

Yahoo Finance report covering Celldex Therapeutics Inc. (CLDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Celldex Therapeutics: Trying To Put Its Troubled History Behind It (NASDAQ:CLDX)

Seeking Alpha report covering Celldex Therapeutics Inc. (CLDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Celldex Therapeutics, Inc. Estimates – NASDAQ:CLDX

TradingView report covering Celldex Therapeutics Inc. (CLDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 1d ago

Learn Why The Bull Case For Celldex Therapeutics Stock Could Change Following Shareholder Investigation

Simply Wall St report covering Celldex Therapeutics Inc. (CLDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Celldex Therapeutics, Inc. (CLDX) Seasonal returns chart

Yahoo Finance UK report covering Celldex Therapeutics Inc. (CLDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Weekly Recap: Physicians favor barzolvolimab and $64–$88 analyst range

TradingView report covering Celldex Therapeutics Inc. (CLDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Is Celldex Therapeutics (CLDX) Below Fair Value Following The Board Investigation?

Simply Wall St report covering Celldex Therapeutics Inc. (CLDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

Understanding Momentum Shifts in (CLDX)

Stock Traders Daily report covering Celldex Therapeutics Inc. (CLDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLDX Bull vs. Bear Conversation Board — What's Your Call at $30.10?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLDX 🐻 33% BEARISH CONVICTION

BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $39.13 (+30.0%)

📌 Pinned Debate

Gross margin of 87.1% and a CATALYST-flagged news item indicate strong unit economics and potential upside if operating losses narrow.

Here is why I am bullish on CLDX here at $30.10: Gross margin of 87.1% and a CATALYST-flagged news item indicate strong unit economics and potential upside if operating losses narrow.. Compare CLDX's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: In Vitro & In Vivo Diagnostic Substances. As long as cash conversion holds up, dips toward $28.59 are getting bought.

RetailWhale_TX 🐂 BULL

Both sides have a point here — CLDX's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $25.59 (-15.0%)

Spot @ $30.10

Free cash flow of -$213.7M against $28.9M of cash and an RQD score of 28 (Grade E) point to significant forensic and liquidity risk.

Free cash flow of -$213.7M against $28.9M of cash and an RQD score of 28 (Grade E) point to significant forensic and liquidity risk.. Look at the math on CLDX: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: In Vitro & In Vivo Diagnostic Substances demand softens. I'd wait for a retest of $26.49 before getting long.